Aims: Prior cost-effectiveness analyses on osseointegrated prosthesis for transfemoral unilateral amputees have analyzed outcomes in non-USA countries using generic quality of life instruments, which may not be appropriate when evaluating disease-specific quality of life. These prior analyses have also focused only on patients who had failed a socket-based prosthesis. The aim of the current study is to use a disease-specific quality of life instrument, which can more accurately reflect a patient's quality of life with this condition in order to evaluate cost-effectiveness, examining both treatment-naïve and socket refractory patients., Methods: Lifetime Markov models were developed evaluating active healthy middle-aged male amputees. Costs of the prostheses, associated complications, use/non-use, and annual costs of arthroplasty parts and service for both a socket and osseointegrated (OPRA) prosthesis were included. Effectiveness was evaluated using the questionnaire for persons with a transfemoral amputation (Q-TFA) until death. All costs and Q-TFA were discounted at 3% annually. Sensitivity analyses on those cost variables which affected a change in treatment (OPRA to socket, or socket to OPRA) were evaluated to determine threshold values. Incremental cost-effectiveness ratios (ICERs) were calculated., Results: For treatment-naïve patients, the lifetime ICER for OPRA was $279/quality-adjusted life-year (QALY). For treatment-refractory patients the ICER was $273/QALY. In sensitivity analysis, the variable thresholds that would affect a change in the course of treatment based on cost (from socket to OPRA), included the following for the treatment-naïve group: yearly replacement components for socket > $8,511; cost yearly replacement parts OPRA < $1,758; and for treatment-refractory group: yearly replacement component for socket of > $12,467., Conclusion: The use of the OPRA prosthesis in physically active transfemoral amputees should be considered as a cost-effective alternative in both treatment-naïve and treatment-refractory socket prosthesis patients. Disease-specific quality of life assessments such as Q-TFA are more sensitive when evaluating cost-effectiveness., Competing Interests: J. Voigt reports payment from Integrum for analysis and writing of this article. J. A. Forsberg reports an institutional grant from the US Navy Bureau of Medicine and Surgery, institutional funding for two osseointegration clinical trials from the US Army, and institutional research support from Zimmer Biomet, consulting fees and payment for expert testimony from The Solsidan Group, payment or honoraria for lectures, presentations, speakers bureuas, manuscript writing or educational events from the Canadian Orthopaedic Society and Japanese Orthopaedic Society, stock or stock options in Prognostix AB, and a US patent (10,952,774), all of which are unrelated to this study. D. H. Melton reports consulting fees from Paradigm Corp unrelated to this study, and sits on the External Advisory Panel of the Limb Loss Preservation Registry, funded by the National Institutes of Health/Department of Defence funded grant. B. K. Potter reports research funding from the US Navy BUMED, CDMRP, DHA, and the National Institutes of Health, unrelated to this study. J. M. Souza reports consulting fees from Checkpoint, Integrum, and Balmoral, and travel expenses from Integrum, Hanger, and Balmoral, all of which are unrelated to this study. B. Wilke reports research support from Avanos and Summit Medical, unrelated to this study., (© 2024 Voigt et al.)